Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Generic Drug Manufacturer Inspections Under OIG Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA notes its efforts to beef up foreign inspections in GDUFA performance report to Congress.

You may also be interested in...



FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections

CDER’s Woodcock says the new database will drive risk-based inspection decisions.

Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting

FDA has essentially shut down Ranbaxy’s three-year-old facility at Mohali as a source for products for the US market. But Ranbaxy is not alone among Indian firms in its quality product disputes with the agency. There is a significant uptick in activity by FDA in the region in what appears to be a period of intense culturization for the Indian firms into the ways FDA enforces cGMPs and handles on-site inspections.

FDA Quality Profiling: Agency Hopes to Channel Corporate Attention (And Money) To Quality Systems

FDA’s drug compliance leadership sees new risk assessment authority for setting inspection schedules from FDASIA as an appealing foundation for collecting and preparing profiles of drug manufacturers. Just don’t call them “report cards.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel